EPO treatment in FRDA patients increased lymphocyte FXN levels, reduced levels of 8-OHdG back to baseline, and promoted neurological score improvement over 8 weeks (Boesch et al., 2007). This evidence concerns the gene EPO and Friedreich ataxia.